CNSP News and Press, CNS Pharmaceuticals Inc. From 05/18/22

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting PR Newswire HOUSTON , May 18, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS"...

The American Society for Radiation Oncology recently released a new clinical guideline that offers guidance on how radiation therapy should be used when treating brain metastases. Brain metastases are tumors that develop when cancer cells from a primary tumor located in another part of the...

CNS Pharmaceuticals press release (NASDAQ:CNSP): Q1 GAAP EPS of -$0.07 beats by $0.04. As of March 31, 2022, the company had cash of approximately $12.4M and working capital of approximately $13.7M. The company's current expectation is that the cash on hand and the proceeds from the offering ...

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Recent approvals of potentially pivotal Berubicin Study into Switzerland , France , and Spain expected to significantly drive patient enrollment ...

When cancer cells spread to the brain, they lead to the formation of brain metastases. Metastases are the primary cause of mortality and morbidity linked to cancer. Researchers at Instituto de Medicina Molecular have developed models to study brain metastases, which may help to better unde...

A new study has found that a drug that is commonly used to hormonally treat conditions such as prostate cancer , early puberty and excessive hair growth may be linked to a heightened risk of meningioma. The study was carried out by researchers at the University of Bristol who collaborated w...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“...

The Departments of Pathology, Neurosurgery and Gynecology/Obstetrics and the Kimmel Cancer Center at Johns Hopkins have received almost $8 million for new research projects to discover cures for a number of fatal cancers, including ovarian cancer, pancreatic cancer and glioblastoma. The pr...

Scientists at the University of Sussex may have discovered a way to decrease the speed at which glioblastoma grows and strengthen potential treatments for the brain tumor. Glioblastoma is a common tumor found in adults. This aggressive tumor is often resistant to treatment, making it fatal...

CNS Pharmaceuticals (NASDAQ:CNSP) said on Thursday that it received approval from Spanish drugs regulator AEMPS and Spanish ethics committee CElm Provincial de Sevilla to conduct a study of Berubicin to treat recurrent glioblastoma multiforme (GBM), an aggressive type of brain cancer. The Spa...